<DOC>
	<DOCNO>NCT02418104</DOCNO>
	<brief_summary>This randomize , double-blind , 2-period parallel study healthy subject assess immunogenicity safety two sequential 6 mg subcutaneous ( SC ) injections CHS-1701 compare two sequential 6 mg SC injection Neulasta® .</brief_summary>
	<brief_title>Assessing Immunogenicity 2 Subcutaneous Doses CHS-1701 ( Coherus Pegfilgrastim ) With 2 Subcutaneous Doses Neulasta®</brief_title>
	<detailed_description />
	<criteria>1 . Adult male female age 18 50 inclusive 2 . Body weight &gt; 50 kg ( 110 lb . ) body mass index 18 32 kg/m2 inclusive 3 . Medically healthy clinically insignificant finding base medical history , 12lead ECG , physical examination 4 . Negative urine pregnancy test woman childbearing potential 1 . Previous exposure pegfilgrastim filgrastim , know allergy PEG ( polyethylene glycol ) 2 . Chemistry hematology value outside protocol specify range 3 . Current previous cancer , diabetes , clinically significant cardiovascular , metabolic , renal , hepatic , gastrointestinal , hematologic , respiratory , dermatological , neurological , psychiatric , disorder 4 . History chronic acute respiratory illness within past 4 week 5 . Positive urine drug alcohol screen unwillingness abstain alcohol recreational drug duration study participation 6 . No prescription nonprescription drug study 7 . Participation investigational clinical study within 30 day prior screen 8 . Known suspected allergic reaction latex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>